Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GSK to Supply Tenozet by Imports from Gilead
December 15, 2015
- Astellas Joins Hands with US Biopharma Bellicum on Cancer Cell Therapy
December 14, 2015
- Novartis Submits Business Improvement Plan over ADR Reporting Delays
December 14, 2015
- ASKA to Launch Authorized Generics of Unisia in March
December 14, 2015
- Ono Files Opdivo for Kidney Cancer, Third Indication in Japan
December 14, 2015
- Mundipharma to Link Up with Shionogi on Isodine Brand, Dissolve Ties with Meiji Seika Pharma
December 11, 2015
- M&As among Generic Makers Would Reap No Benefits: Sawai President
December 11, 2015
- Sumitomo Dainippon to Launch 3 Pivotal Trials for Napabucasin in FY2015, Postpone BBI503 Program
December 10, 2015
- Sumitomo Dainippon to Begin Lurasidone PIII within FY2015, 3rd Attempt for Schizophrenia Indication
December 10, 2015
- Mitsubishi Chemical Holdings to Invest in New Production Facilities for Drugs and Vaccines
December 10, 2015
- Stephen Hitchcock Tapped as Head of Pharma Research at Takeda
December 9, 2015
- Takeda Ties Up with US Biotech Cour on Immune Modulating Therapies
December 9, 2015
- Ethical Drug Sales Zoom 10.7% in October: Crecon Report
December 9, 2015
- Mega Mergers Not the Best Way to Get Drug Discovery Prowess: Astellas President
December 9, 2015
- Sovaldi Top-Prescribed Drug at Japanese Acute Hospitals in July-Sept.
December 8, 2015
- Belsomra Most Promoted Drug for GPs for 4 Months Running: Anterio
December 8, 2015
- Otsuka Seeks Japan Approval of Abilify for Juvenile Autism-Linked Excitability
December 8, 2015
- MM Treatment Ixazomib Extends PFS in PIII: Takeda
December 8, 2015
- Nothing Decided for Japan Market over Pfizer’s Allergan Acquisition: Umeda
December 7, 2015
- Global PII for Pediatric X-Linked Hypophosphatemia Yields Positive Data: Kyowa Kirin
December 7, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…